GenSpera harnesses a novel biomedical technology platform to deliver a powerful toxin directly to tumors

Phase II clinical trials for lead compound for mipsagargin, also known as G-202, are underway in two indications:
Hepatocellular carcinoma, or
Glioblastoma, or brain cancer
Experienced and motivated team drives the process:
Core team has extensive experience in successfully identifying and bringing oncology treatments to the clinic.
Scientific Advisory Board is comprised of leading researchers who are both the inventors of the technology and shareholders.
Technology platform supports the development of a suite of drugs targeted at different cancers, as well as other applications such as imaging.
Over 15 years of research at Johns Hopkins Medical Center and other renowned research centers, including the University of Copenhagen.
Strong intellectual property portfolio
No milestones or royalty payments owed to third parties.
Leverage the team’s passion and expertise in identifying promising treatments and bringing them to the clinic.